Vascular Disease Management
INSIGHT INTO DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
MANAGEMENT
Friday, August 8, 2008

SEARCH ARTICLES



Home | About
Current Issue
Archives
Subscribe
Board Members
Search Article Archives
Editor's Update
Events & Symposia
Industry News | Enews
Discussion Forum
Classifieds
Letter to the Editor
Comments/Suggestions
Editorial/Production
Author Information
Submit a Manuscript
Review a Manuscript
Order Article Reprints
Advertising
Advertising Specs
Online/Web Production

Featured Article

Cardiac Surgery Disrupted: The “Dark Side of Innovation” vs. Foresight Failure
Editor's Corner:
Cardiac Surgery Disrupted: The “Dark Side of Innovation” vs. Foresight Failure

- Frank J. Criado




I’d bet the majority of the VDM readership (and Medicine at large) would rank cardiac surgery (CS) amongst the top and most-respected specialties — and for good reasons. For many years, heart surgeons have been some of the busiest and best-paid physicians in the country. Their work is often linked to “miraculous cures” and “great saves”…. After all, only the brain can compete with the heart to inspire awe and capture everyone’s imagination. They have been, one might say, “almost alone in that small high place reserved for those chosen to be at the top.”

Now, fast forward to 2007, the November/December issue of VDM, and open to page 175. You will find an informative and well-written article by Ailawadi and Kron that examines the current status of CS: a far cry for sure from the glorious days of yesteryear. This piece on “The Challenges Facing Cardiothoracic Surgeons” is a timely and excellent review of something I suspect — and, in fact, predict — will be studied and talked about for many years to come. The “descent” of cardiac surgery to a zone of challenge, difficulty, and uncertainty about its future is nothing short of an incredible story. Just how did this happen? How did they get from there to here? And here represents a much lower pay, the precipitous decline in the number of bread-and-butter coronary bypasses, a near-total lack of control of patient care, a historically-disastrous non-embrace of new technologies and techniques that have now replaced much of their daily surgical work, the inability to attract enough candidates to their ranks and to fill a majority of residency slot positions… and more. The aforementioned article is a must-read for all those interested in these matters (nearly everyone I would hope); it includes a well-written and complete discussion of what we might call “the anatomy of a disrupted specialty.” I’d simply like to emphasize a few issues that are close to…. well, my heart!

1. The power of disruptive innovative technologies cannot be overemphasized. It was the focus of two Editor’s Corner articles in this journal (2005’s September/October and November/December issues). In truth, the heart has been and is “disruption and innovation-central” for all vascular and endovascular technologies. The enormous impact is now felt everywhere and by everyone.

2. CS failed to recognize the potential of these technologies to overtake their field. And perhaps they were “too busy to pay attention”…. For whatever reason, the failures to embrace and retrain and reinvent (themselves) have resulted — more than anything else — in the reality they now live and confront.

3. The perception and reality of cardiac surgeons as “technicians” (albeit highly skilled, educated, and well paid) have been significant factors as well. Cardiac surgeons are not in control of the patient and do not manage the underlying disease. Unlike vascular surgeons, they seem to have accepted a gradual but unmistakable move in that direction. It was shortsighted and made them vulnerable. Period. While sharing with cardiac surgeons some of the same historic challenges, vascular surgeons retained (throughout) their preeminence as the vascular specialists, with overall responsibility for vascular care — not just procedures. We overcame some of the same issues earlier and perhaps in a more effective way, mainly because of the vascular-practice scenario and the fact that referrals have always been directed to the vascular surgeon, who has been and continues to be regarded as the vascular specialist — not just the one to operate or do a procedure.

4. The significant decrease in reimbursement rates for CS procedures was inevitable, and in line with the rest of the medical and economic landscape in the USA at this time. But it has added another layer of dissatisfaction and challenge that, when put together with the rest, contributes in a measurable way to making CS a less desirable destination as a specialty for new physicians.

5. The sharp decline in interest in CS and the predicted significant shortage of cardiac surgeons over the next 10–20 years is a huge issue for medicine in general and the country as a whole. While advanced less-invasive and even non-surgical technologies will be able to address many of the former “surgical” heart problems, there will continue to be a great number of clinical situations and patients that can only be repaired with “classic” open CS. I don’t see this changing in the foreseeable future.

Are the above-described problems serious? Obviously yes! Are there further challenges down the road? Another yes, particularly as they relate to the development of new technologies and approaches to treatment of structural heart disease — valves in particular. However, one can only hope that cardiac surgeons have learned the lessons of the past 2 decades and will hopefully behave in a more proactive and embracing fashion this time around. Additionally, there are and will be, undoubtedly, new opportunities for CS to shine again, and some of these are discussed in Ailawadi and Kron’s article. And there are the re-training and re-invention scenarios many cardiac surgeons have now embarked upon. Endograft aortic technologies and peripheral endovascular opportunities abound, and no doubt, they will become a major focus for many cardiac surgeons today and tomorrow. Interestingly, such pursuits may well send them into a “collision course” with vascular surgeons who have led such efforts from the beginning…. No one can predict the end result of these interplays, but it will surely be interesting to watch!

So, in the end, was CS' disruption caused by technological innovation or self-inflicted foresight failure? Or, perhaps, an “act of God”.... I'll let the reader decide.


Vascular Disease Management - ISSN: 1553-8036 - Volume 4 - Issue 6 - November 2007 - Pages: A4 - A6

VASCULAR TOPICS

Peripheral Angioplasty
Thoracic Stent Grafts
Renal Stenting
Vena Cava Filter
Hemodialysis Management
Computed Tomography
PFO Closure
SFA Stenting
Carotid Stenting
Vessel Closure
Angiography
Carotid Endarterectomy
Ultrasound

Critical Limb Ischemia
Superficial Femoral Artery
Embolization
Device Based Thrombectomy
Pharmacological Management
MRA
Mesenteric Artery Stenting
AAA Stent Grafts
Iliac Stenting
Thrombolysis Procedures Using Drug Therapy

SUPPLEMENTS

Superior Mesenteric Artery Revascularization and Retrograde Visualization
This clinical case update was supported through an unrestricted educational grant from Terumo Medical Corporation.

HMP Increased Cutaneous Sensibility in Patients with Diabetic Neuropathy Utilizing a Pharmacological Approach — Clinical Case Evidence

This clinical case update was supported through an unrestricted educational grant from Pamlab, LLC.

A New Biological Approachto Below-Knee Revascularization
A Review of the GORE PROPATEN Vascular Graft:
The Combination That Lasts

This special supplement was made possible through a grant from W. L. Gore

Combining Bilayered Living Cell Therapy with Minimally Invasive Vein Surgery:
Current Treatment Strategies for Venous Ulcers

This activity is supported by an educational grant from Organogenesis.

Pharmacotherapy in Peripheral Vascular Disease

Platelet Inhibition in Critical Limb Ischemia and Peripheral Vascular Interventions
DAVID E. ALLIE, MD

An Overview of Pharmacotherapy during Percutaneous Peripheral Interventions of Thrombotic Lesions
NICOLAS W. SHAMMAS, MD, MS, FACC


The Important Properties of Contrast Media: Focus on Viscosity

This special supplement was made possible through a grant from Guerbet LLC

RECENTLY ADDED

Anticoagulation Techniques for Peripheral Vascular Interventions

Archived Webcast





About HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC, which also owns the North American Center for Continuing Medical Education (NACCME). NACCME provides a wide array of accredited CME offerings with industry thought leaders participating in roundtable meetings, webcasts, symposia, conferences, seminars, podcasts and satellite programs. Discover more about HMP’s products and services at www.hmpcommunications.com. ©2008 HMP Communications

© 2008 HMP Communications | All Rights Reserved
83 General Warren Blvd., Suite 100, Malvern, PA 19355
Phone: 800.237.7285 610.560.0500 Fax: 610.560.0502
Privacy Policy